Scancell Company

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Technology: Drug Discovery
Industry: Personalized Medicine
Headquarters: Nottingham, Nottingham, United Kingdom
Founded Date: 1996
Employees Number: 11-50
Funding Status: IPO

Visit Website
scancell@fticonsulting.com
@scancellpharma
Register and Claim Ownership